Drug therapy safety with patients in facilities of the long-term care

Drug therapy safety with patients in facilities of the long-term care - AMTS-AMPEL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00004952

Enrollment

1000

Registered

2013-05-16

Start date

2013-09-24

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All adverse drug events (ADE)! T88.7

Interventions

Group 1: The intervention includes training for all professional groups involved (nursing staff, family doctors, pharmacists) . In the facilities of the long-term care, we establish AMTS-teams (pharma

Eligibility

Sex/Gender

All

Age

65 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patient consent form. Occurring ADE.

Exclusion criteria

Exclusion criteria: No patient consent form.

Design outcomes

Primary

Measure	Time frame
As primary endpoint of our study, reduction of ADE will be analyzed by comparing 30-day-prevalence of ADE of the pre-interventional assessment versus 6 months after starting the intervention (adjusted for nursing homes).	—

Secondary

Measure	Time frame
As secondary endpoints, newly occurring ADE and number of relevant clinical endpoints (e.g. hospitalization) will be evaluated. After a first survey there will be a second cross-sectional analysis after 6 months and a third survey after 12 months.	—

Countries

Germany

Contacts

Public ContactPetra Thürmann

Universität Witten/Herdecke, Inst. f. Klinische Pharmakologie, Fakultät f. Gesundheit

petra.thuermann@uni-wh.de0202-896-1869

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026